Brilliance Asset Management LTD Novo Cure LTD Transaction History

Brilliance Asset Management LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$116.17 - $194.55 $7.59 Million - $12.7 Million	-65,351 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$130.4 - $225.58 $912,800 - $1.58 Million	-7,000 Reduced 9.68%	65,351 $14.5 Million
Q1 2021 May 14, 2021	BUY	$124.11 - $190.17 $868,770 - $1.33 Million	7,000 Added 10.71%	72,351 $9.56 Million
Q4 2020 Feb 16, 2021	SELL	$112.16 - $174.14 $8.17 Million - $12.7 Million	-72,801 Reduced 52.7%	65,351 $11.3 Million
Q3 2020 Nov 13, 2020	BUY	$58.05 - $111.31 $8.02 Million - $15.4 Million	138,152 New	138,152 $15.4 Million

277

73.2M

1.43M

832K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.77B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Brilliance Asset Management LTD, based on Form 13F filings with the SEC.

Stay updated on Brilliance Asset Management LTD with notifications on news.